sponsored
PatientsVille.com Logo

PatientsVille

Recothrom Medical Research Studies

Up-to-date List of Recothrom Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Recothrom Medical Research Studies

Rank Status Study
1 Recruiting A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding
Conditions: Ulcer, on Gastric Varices;   Rebleeding From Gastric Varices
Interventions: Drug: Thrombin;   Drug: Histoacryl
Outcome Measures: Ulcer on gastric varices;   rebleeding
2 Recruiting Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Open Surgeries
Condition: Hemostasis
Interventions: Biological: Human thrombin;   Biological: Bovine thrombin
Outcome Measures: Proportion of subjects achieving hemostasis at the TBS;   Treatment-emergent adverse events
3 Not yet recruiting The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.
Condition: Iron-Deficiency Anemias,
Intervention:
Outcome Measure: thrombin generation levels
4 Recruiting Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations
Condition: Cerebral Venous Thrombosis
Intervention:
Outcome Measures: Evolution of thrombin generation parameters;   Evolution of D Dimers concentration;   Evolution of thrombin generation parameters after end of treatment;   MR Imaging and Thrombin generation parameters;   MR Imaging and D Dimers concentration;   Evolution of D Dimers concentration after treatment
5 Recruiting Evaluating the Role of Thrombin in Saphenous Vein Graft Failure After Heart Bypass Surgery
Conditions: Coronary Artery Bypass;   Thrombosis
Intervention:
Outcome Measures: Amplifying the severity of all three risk factors of Virchow's triad is expected to lead to a synergistic increase in regional thrombin formation;   Pressure distention is the main stimulus that creates a loss of thrombin control within the SVG;   Accurate tests of graft quality will be developed that provide rapid results for ready translation into clinical applications;   Aprotinin or bivalirudin will effectively suppress thrombin generation and its effects within the highest risk grafts
6 Recruiting Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Intervention:
Outcome Measures: change from baseline in Thrombin generation measure;   image-confirmed venous thromboembolic events;   change from baseline in TFPI resistance measure;   change from baseline in acquired protein S deficiency measure
7 Recruiting Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
Condition: Severe Hemophilia A With Inhibitor
Intervention: Other: TGA (Thrombin generation Assay)
Outcome Measures: Thrombin generation result;   Epitope mapping results;   Incidence of all breakthrough (BT) bleedings;   Total FVIII dose required to treat the patients;   the inhibitor titre course;   Use of bypassing agents;   ITI outcome only for patient under this kind of treatment
8 Recruiting Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery
Condition: Adolescent Idiopathic Scoliosis
Intervention: Device: Gelatin matrix with human derived thrombin (Floseal, Baxter)
Outcome Measures: Total perioperative blood loss;   Used blood products;   Blood loss during surgery;   Time of surgery
9 Recruiting Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
Condition: Staphylococcus Aureus Bacteraemia
Interventions: Drug: direct thrombin inhibition;   Drug: enoxaparin
Outcome Measures: Primary Safety Outcome is the occurence of clinically-relevant bleeding events;   The primary efficacy outcome is the occurence of metastatic infection
10 Unknown  Athermal Nerve-sparing During Robotic-assisted Radical Prostatectomy Using a Hemostatic Matrix.
Conditions: Prostate Cancer;   Erectile Dysfunction
Interventions: Procedure: Application of a hemostatic gelatin-thrombin matrix;   Procedure: Use of mono- and bipolar electrocautery and surgical clips
Outcome Measures: Postoperative erectile function;   Postoperative continence;   Intraoperative bloodloss;   Intra- and postoperative complications
11 Unknown  Thrombin Regulated Platelet Activation
Conditions: Coronary Artery Disease;   Acute Coronary Syndrome
Intervention:
Outcome Measure:
12 Not yet recruiting Anti-thrombin III (ATIII) vs Placebo in Children (<6mo) Undergoing Open Congenital Cardiac Surgery
Condition: ATIII Deficiency
Interventions: Drug: Anti-thrombin III;   Other: Placebo
Outcome Measures: Decreased activation of the coagulation and fibrinolytic systems;   Total dose of heparin and protamine;   Total volume of blood products;   Time from protamine administration to skin dressing;   Volume of postoperative blood loss;   Volume of blood products;   Use of recombinant factor VIIa;   Safety profile of ATIII dosing;   Length of post operative ventilation
13 Recruiting Thrombin Generation and Gestational Outcome
Condition: Thrombophilia
Intervention:
Outcome Measure: pregnancy outcome
14 Recruiting Does Deficiency in Vitamin D Induced Hypercoagulation or Thrombin Generation
Condition: Cardiovascular Disease
Intervention: Drug: Vitamin D
Outcome Measure: the correlation between vitamin D levels and endogenous thrombin potential
15 Unknown  Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria
Condition: Paroxysmal Nocturnal Haemoglobinuria
Intervention:
Outcome Measures: To establish the role of thrombin generation in assessing the prothrombotic phenotype of PNH;   To establish the role of thromboelastometry in evaluating the prothrombotic phenotype of PNH;   To establish effects of eculizumab treatment on thrombin generation and thromboelastometry
16 Recruiting A Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Subjects With Hemophilia A Or B
Condition: Hemophilia A
Intervention: Biological: PF-05280602
Outcome Measures: Incdence of subjects wtih treatment emergent adverse events;   Incidence of of subjects with treatment emergent hemophilia adverse events;   Incidence of subjects with treatment emergent serious adverse events;   Changes from baseline in patient's vital signs- blood pressure;   Changes from baseline in patient's ECG;   Changes from baseline in patient's physical examination;   Incidence of treatment emergent clinical laboratory abnormalities for Tropin T levels;   Magnitude of treatment emergent clinical laboratory abnormalities for Troponin T levels;   Incidence of an immune response;   Incidence of treatment emergent clinical laboratory abnormalities for Anti-Thrombin III;   Incidence of treatment emergent clinical laboratory abnormalities for Tissue Factor Pathway Inhibitor;   Number of subjects with clinically significant changes from baseline in their fibrinogen;   Changes from baseline in patient's vital signs- weight;   Changes from baseline in patient's vital signs- temperature;   Changes from baseline in patient's vital signs- respiration rate;   Changes from baseline in patient's vital signs- pulse rate;   Severity of subjects wtih treatment emergent adverse events;   Severity of of subjects with treatment emergent hemophilia adverse events;   Severity of subjects with treatment emergent serious adverse events;   Withdrawals due to treatment emergent adverse events;   Withdrawals due to treatment emergent hemophilia events;   Incidence of treatment emergent clinical laboratory abnormalities for hematology;   Magnitude of treatment emergent clinical laboratory abnormalities for hematology;   Incidence of treatment emergent clinical laboratory abnormalities for chemistry;   Magnitude of treatment emergent clinical laboratory abnormalities for chemistry;   Incidence of treatment emergent clinical laboratory abnormalities for urinalysis;   Magnitude of treatment emergent clinical laboratory abnormalities for urinalysis;   Incidence of treatment emergent clinical laboratory abnormalities for platelet count;   Magnitude of treatment emergent clinical laboratory abnormalities for platelet count;   Magnitude of treatment emergent clinical laboratory abnormalities for Anti-Thrombin III;   Magnitude of treatment emergent clinical laboratory abnormalities for Tissue Factor Pathway Inhibitor;   Incidence of treatment emergent clinical laboratory abnormalities for C-Reactive Protein;   Magnitude of treatment emergent clinical laboratory abnormalities for C-Reactive Protein;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, Cmax;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, area under the curve (AUC last);   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, terminal half-life;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, recovery;   Pharmacodynamic (Hematologic) activity as measured by the Prothrombin Time;   Pharmacodynamic (Hematologic) activity as measured by the activated partial thrombinplastin time;   Pharmacodynamic (Hematologic) activity as measured by the thrombin antithrombin complexes;   Pharmacodynamic (Hematologic) activity as measured by the prothrombin fragments 1+2;   Pharmacodynamic (Hematologic) activity as measured by D-Dimers;   Pharmacodynamic (Hematologic) activity as measured by thrombin generation;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, area under the curve (AUC inf);   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, mean residence time;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, Vss;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, clearance;   Factor VIIa concentration in subject plasma as measured by FVIIa PK assay, Tmax
17 Recruiting Triple vs. Dual Therapy
Conditions: Atrial Fibrillation;   Acute Coronary Syndrome
Interventions: Drug: Ticagrelor + Apixaban + ASA;   Drug: Ticagrelor + Apixaban
Outcome Measures: β-thromboglobulin (β-TG);   Prothrombin fragment F1+2 (F1+2);   Thrombin-Anti-Thrombin (TAT);   D-dimer;   P-selectin
18 Unknown  Study of Coagulation Activation Markers and Pre Eclampsia
Condition: Pre Eclampsia
Intervention:
Outcome Measures: Endogenous thrombin potential;   genotype-phenotype correlation (Polymorphism of prostacyclin-synthetase promoter CYP8A1;   In preeclampsia group : correlation between biological markers and severity of the disease;   evolution of endogenous thrombin potential in women with preeclampsia
19 Unknown  Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin
Condition: Coronary Artery Disease
Intervention: Drug: Bivalirudin with and without eptifibatide
Outcome Measures: Compare the antiplatelet effects of clopidogrel+bivalirudin vs. clopidogrel+bivalirudin+eptifibatide in patients undergoing elective percutaneous intervention;   Compare the release of myocardial necrosis and inflammatory markers;   Measure platelet reactivity with conventional light transmittance aggregometry and thrombelastography;   Assess in-hospital 30 day, and 1 year clinical outcomes.
20 Unknown  Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects
Condition: Acute Coronary Syndrome
Interventions: Drug: simvastatin;   Drug: ezetimibe;   Drug: placebo
Outcome Measures: decrease in thrombin generation;   increase in clot permeability

These studies may lead to new treatments and are adding insight into Recothrom etiology and treatment.

A major focus of Recothrom research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Recothrom